• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Leukemias - Pipeline Review, H2 2012 Product Image

Leukemias - Pipeline Review, H2 2012

  • Published: December 2012
  • 866 pages
  • Global Markets Direct

Leukemias – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Leukemias - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemias. Leukemias - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leukemias.
- A review of the Leukemias products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 25
List of Figures 35
Introduction 36
REPORT COVERAGE 36
Leukemias Overview 37
Therapeutics Development 38
An Overview of Pipeline Products for Leukemias 38
Leukemias Therapeutics under Development by Companies 40
Leukemias Therapeutics under Investigation by Universities/Institutes 56
Late Stage Products 74
Comparative Analysis 74
Mid Clinical Stage Products 75
Comparative Analysis 75
Early Clinical Stage Products 76
Comparative Analysis 76
Discovery and Pre-Clinical Stage Products 77
Comparative Analysis 77
Leukemias Therapeutics – Products under Development by Companies 78
Leukemias Therapeutics – Products under Investigation by Universities/Institutes 103
Companies Involved in Leukemias Therapeutics Development 173
Bristol-Myers Squibb Company 173
Genzyme Corporation 174
Baxter International Inc. 175
Boehringer Ingelheim GmbH 176
F. Hoffmann-La Roche Ltd. 177
Kyowa Hakko Kirin Co., Ltd. 178
Abbott Laboratories 179
Amgen Inc. 180
Sanofi-Aventis 181
AstraZeneca PLC 182
Eli Lilly and Company 183
Athersys, Inc. 184
GlaxoSmithKline plc 185
Seattle Genetics, Inc. 186
Genentech, Inc. 187
MedImmune LLC 188
Gilead Sciences, Inc. 189
medac GmbH 190
Merck & Co., Inc. 191
Emergent BioSolutions Inc. 192
Lentigen Corporation 193
Otsuka Pharmaceutical Co., Ltd. 194
Gamida Cell Ltd. 195
Generex Biotechnology Corporation 196
Plexxikon Inc. 197
BioLineRx, Ltd. 198
Amorfix Life Sciences Ltd. 199
Piramal Healthcare Limited 200
Celltrion, Inc. 201
Bio-Path Holdings, Inc. 202
BioSante Pharmaceuticals, Inc. 203
ZIOPHARM Oncology, Inc. 204
Millennium Pharmaceuticals, Inc. 205
Novartis AG 206
BioMarin Pharmaceutical Inc. 207
Daewoong Pharmaceutical Co., Ltd. 208
Eisai Co., Ltd. 209
Gedeon Richter Plc. 210
Glenmark Pharmaceuticals Ltd. 211
ImmunoGen, Inc. 212
Nippon Shinyaku Co., Ltd. 213
Pfizer Inc. 214
Sunesis Pharmaceuticals, Inc. 215
SuperGen, Inc. 216
Teva Pharmaceutical Industries Limited 217
Kinex Pharmaceuticals, LLC 328
Biokine Therapeutics Ltd. 329
OncoImmune, Inc. 330
Cylene Pharmaceuticals, Inc. 331
GlycoMimetics, Inc. 332
Lipopharma 333
Biothera 334
Nereus Pharmaceuticals, Inc. 335
CytImmune Sciences, Inc. 336
Keystone Nano, Inc. 337
Advanced Cancer Therapeutics 338
Sigma-Tau Pharmaceuticals, Inc. 339
Cancer Therapeutics CRC Pty Ltd 340
LFB Biotechnologies, S.A.S.U. 341
Interprotein Corporation 342
EpiZyme, Inc. 343
Targa Therapeutics Corp. 344
Jiangsu Kanion Pharmaceutical Co., Ltd. 345
KAEL-GemVax 346
Sentinel Oncology Limited 347
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 348
iCeutica, Inc. 349
Polaris Group 350
ImQuest Life Sciences 351
Immunovative Therapies, Ltd. 352
Herbert Irving Comprehensive Cancer Center 353
BerGenBio AS 354
Advancell 355
Leukemias – Therapeutics Assessment 356
Assessment by Monotherapy Products 356
Assessment by Combination Products 357
Assessment by Route of Administration 358
Assessment by Molecule Type 360
Drug Profiles 363
StemEx - Drug Profile 363
Product Description 363
Mechanism of Action 363
R&D Progress 363
Ofatumumab + Chlorambucil - Drug Profile 419
Product Description 419
Mechanism of Action 419
R&D Progress 419
Proleukin + Maxamine - Drug Profile 420
Product Description 420
Mechanism of Action 420
R&D Progress 420
Cyclophosphamide + Busulfan + Peripheral Blood Stem Cell Transplantation + Tacrolimus + Methotrexate - Drug Profile 422
Product Description 422
Mechanism of Action 422
R&D Progress 423
Fludara + Cytoxan + Rituxan - Drug Profile 424
Product Description 424
Mechanism of Action 424
R&D Progress 424
inotuzumab ozogamicin - Drug Profile 425
Product Description 425
Mechanism of Action 425
R&D Progress 425
Cytarabine + Idarubicin + Mitoxantrone + All-Trans-Retinoic Acid + Etoposide - Drug Profile 487
Product Description 487
Mechanism of Action 487
R&D Progress 487
Imatinib Mesylate + AraC + Stem Cell Transplantation - Drug Profile 489
Product Description 489
Mechanism of Action 489
R&D Progress 489
rituximab - Drug Profile 491
Product Description 491
Mechanism of Action 491
R&D Progress 491
Imatinib Mesylate + Recombinant Interferon Alfa - Drug Profile 492
Product Description 492
Mechanism of Action 492
R&D Progress 492
Cytarabine + Daunorubicin + Etoposide + Filgrastim - Drug Profile 494
Product Description 494
Mechanism of Action 494
R&D Progress 495
Fludarabine + Cytarabine + Filgrastim - Drug Profile 496
Product Description 496
Mechanism of Action 496
R&D Progress 496
Alemtuzumab + Arsenic Trioxide + Azacitidine + Busulfan + Clofarabine + Cytarabine + Daunorubicin Hydrochloride + Fludarabine Phosphate + Gemtuzumab Ozogamicin + Melphalan + Tipifarnib + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 588
Product Description 588
Mechanism of Action 589
R&D Progress 590
Cytarabine+ Idarubicin +Etoposide+ Fludarabine +G-CSF - Drug Profile 591
Product Description 591
Mechanism of Action 591
R&D Progress 592
Cytarabine+ Idarubicin +Etoposide+ All-Trans Retinoic Acid+ Pegfilgrastim - Drug Profile 593
Product Description 593
Mechanism of Action 593
R&D Progress 594
Cytarabine+ Idarubicin All-Trans Retinoic Acid+ Mitoxantrone+ Etoposide - Drug Profile 595
Product Description 595
Mechanism of Action 595
R&D Progress 596
Asparaginase + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Gemtuzumab + Mitoxantrone Hydrochloride - Drug Profile 597
Product Description 597
Mechanism of Action 597
R&D Progress 598
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Mylotarg + Mitoxantrone - Drug Profile 599
Product Description 599
Mechanism of Action 599
R&D Progress 600
sapacitabine - Drug Profile 693
Product Description 693
Mechanism of Action 693
R&D Progress 693
cytarabine - Drug Profile 694
Product Description 694
Mechanism of Action 694
R&D Progress 694
Ara-C + Vosaroxin - Drug Profile 695
Product Description 695
Mechanism of Action 695
R&D Progress 695
Ara-C + AC220 - Drug Profile 696
Product Description 696
Mechanism of Action 696
R&D Progress 696
Gemtuzumab Ozogamicin + Fludarabine + Cytarabine + Idarubicin - Drug Profile 697
Product Description 697
Mechanism of Action 697
R&D Progress 697
GS-1101 + Ofatumumab - Drug Profile 699
Product Description 699
Mechanism of Action 699
R&D Progress 699
calaspargase pegol - Drug Profile 700
Product Description 700
Mechanism of Action 700
R&D Progress 700
Allogeneic Stem Cell Transplantation - Drug Profile 701
Product Description 701
Mechanism of Action 701
R&D Progress 701
cholecalciferol - Drug Profile 702
Product Description 702
Mechanism of Action 702
R&D Progress 702
Bendamustine + Ofatumumab - Drug Profile 703
Product Description 703
Mechanism of Action 703
R&D Progress 703
decitabine - Drug Profile 704
Product Description 704
Mechanism of Action 704
R&D Progress 704
Leukemias Therapeutics – Drug Profile Updates 705
Leukemias Therapeutics – Discontinued Products 742
Leukemias Therapeutics - Dormant Products 765
Leukemias – Product Development Milestones 854
Featured News & Press Releases 854
Nov 21, 2012: Oxigene's OXi4503 Receives Orphan Designation For Treatment Of Acute Myelogenous Leukemia 854
Nov 20, 2012: Astex Pharma Announces Oral Presentation Of SGI-110 Results From Phase I/II MDS And AML Study At ASH 855
Nov 14, 2012: Bio-Path Completes Fourth Cohort In Phase I Clinical Trial Of Liposomal Grb-2 In Leukemia 855
Nov 14, 2012: Bio-Path Completes Fourth Cohort In Phase I Clinical Trial Of Liposomal Grb-2 In Leukemia 857
Nov 14, 2012: Bio-Path Completes Fourth Cohort In Phase I Clinical Trial Of Liposomal Grb-2 In Leukemia 859
Nov 13, 2012: Talon Therapeutics Presents Phase II Data On Marqibo At 2012 Chemotherapy Foundation Symposium 861
Nov 09, 2012: ProNAi Presents Encouraging Phase I Study Results Of PNT2258 At Cancer Meeting 861
Nov 07, 2012: TopoTarget Announces Presentation Of Belinostat Abstract At American Society of Hematology's Annual Meeting 2012 862
Nov 07, 2012: TopoTarget Announces Presentation Of Belinostat Abstract At American Society of Hematology's Annual Meeting 2012 864
Nov 07, 2012: BioLineRx To Present Data On BL-8040 For Treatment Of Leukemia And Other Types Of Hematological Cancer At 2012 ASH Annual Meeting 865
Appendix 866
Methodology 866
Coverage 866
Secondary Research 866
Primary Research 866
Expert Panel Validation 866
Contact Us 867
Disclaimer 867

List of Tables
Number of Products Under Development for Leukemias, H2 2012 38
Products under Development for Leukemias – Comparative Analysis, H2 2012 39
Number of Products under Development by Companies, H2 2012 41
Number of Products under Development by Companies, H2 2012 (Contd..1) 42
Number of Products under Development by Companies, H2 2012 (Contd..2) 43
Number of Products under Development by Companies, H2 2012 (Contd..3) 44
Number of Products under Development by Companies, H2 2012 (Contd..4) 45
Number of Products under Development by Companies, H2 2012 (Contd..5) 46
Number of Products under Development by Companies, H2 2012 (Contd..6) 47
Number of Products under Development by Companies, H2 2012 (Contd..7) 48
Number of Products under Development by Companies, H2 2012 (Contd..8) 49
Number of Products under Development by Companies, H2 2012 (Contd..9) 50
Number of Products under Development by Companies, H2 2012 (Contd..10) 51
Number of Products under Development by Companies, H2 2012 (Contd..11) 52
Number of Products under Development by Companies, H2 2012 (Contd..12) 53
Number of Products under Development by Companies, H2 2012 (Contd..13) 54
Number of Products under Development by Companies, H2 2012 (Contd..14) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 64
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 65
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 66
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 67
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 68
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 69
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 70
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 71
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 72
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 73
Comparative Analysis by Late Stage Development, H2 2012 74
Comparative Analysis by Mid Clinical Stage Development, H2 2012 75
Comparative Analysis by Early Clinical Stage Development, H2 2012 76
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 77
Products under Development by Companies, H2 2012 78
Products under Development by Companies, H2 2012 (Contd..1) 79
Products under Development by Companies, H2 2012 (Contd..2) 80
Products under Development by Companies, H2 2012 (Contd..3) 81
Products under Development by Companies, H2 2012 (Contd..4) 82
Products under Development by Companies, H2 2012 (Contd..5) 83
Products under Development by Companies, H2 2012 (Contd..6) 84
Products under Development by Companies, H2 2012 (Contd..7) 85
Products under Development by Companies, H2 2012 (Contd..8) 86
Products under Development by Companies, H2 2012 (Contd..9) 87
Products under Development by Companies, H2 2012 (Contd..10) 88
Products under Development by Companies, H2 2012 (Contd..11) 89
Products under Development by Companies, H2 2012 (Contd..12) 90
Products under Development by Companies, H2 2012 (Contd..13) 91
Products under Development by Companies, H2 2012 (Contd..14) 92
Products under Development by Companies, H2 2012 (Contd..15) 93
Products under Development by Companies, H2 2012 (Contd..16) 94
Products under Development by Companies, H2 2012 (Contd..17) 95
Products under Development by Companies, H2 2012 (Contd..18) 96
Products under Development by Companies, H2 2012 (Contd..19) 97
Products under Development by Companies, H2 2012 (Contd..20) 98
Products under Development by Companies, H2 2012 (Contd..21) 99
Products under Development by Companies, H2 2012 (Contd..22) 100
Products under Development by Companies, H2 2012 (Contd..23) 101
Products under Development by Companies, H2 2012 (Contd..24) 102
Products under Investigation by Universities/Institutes, H2 2012 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 110
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..53) 157
Products under Investigation by Universities/Institutes, H2 2012 (Contd..54) 158
Products under Investigation by Universities/Institutes, H2 2012 (Contd..55) 159
Products under Investigation by Universities/Institutes, H2 2012 (Contd..56) 160
Products under Investigation by Universities/Institutes, H2 2012 (Contd..57) 161
Products under Investigation by Universities/Institutes, H2 2012 (Contd..58) 162
Products under Investigation by Universities/Institutes, H2 2012 (Contd..59) 163
Products under Investigation by Universities/Institutes, H2 2012 (Contd..60) 164
Products under Investigation by Universities/Institutes, H2 2012 (Contd..61) 165
Products under Investigation by Universities/Institutes, H2 2012 (Contd..62) 166
Products under Investigation by Universities/Institutes, H2 2012 (Contd..63) 167
Products under Investigation by Universities/Institutes, H2 2012 (Contd..64) 168
Products under Investigation by Universities/Institutes, H2 2012 (Contd..65) 169
Products under Investigation by Universities/Institutes, H2 2012 (Contd..66) 170
Products under Investigation by Universities/Institutes, H2 2012 (Contd..67) 171
Products under Investigation by Universities/Institutes, H2 2012 (Contd..68) 172
Bristol-Myers Squibb Company, H2 2012 173
Genzyme Corporation, H2 2012 174
Baxter International Inc., H2 2012 175
Boehringer Ingelheim GmbH, H2 2012 176
F. Hoffmann-La Roche Ltd., H2 2012 177
Kyowa Hakko Kirin Co., Ltd., H2 2012 178
Abbott Laboratories, H2 2012 179
Amgen Inc., H2 2012 180
Sanofi-Aventis, H2 2012 181
AstraZeneca PLC, H2 2012 182
Eli Lilly and Company, H2 2012 183
Athersys, Inc., H2 2012 184
GlaxoSmithKline plc, H2 2012 185
Seattle Genetics, Inc., H2 2012 186
Genentech, Inc., H2 2012 187
MedImmune LLC, H2 2012 188
Gilead Sciences, Inc., H2 2012 189
medac GmbH, H2 2012 190
Merck & Co., Inc., H2 2012 191
Emergent BioSolutions Inc., H2 2012 192
Lentigen Corporation, H2 2012 193
Otsuka Pharmaceutical Co., Ltd., H2 2012 194
Gamida Cell Ltd., H2 2012 195
Generex Biotechnology Corporation, H2 2012 196
Plexxikon Inc., H2 2012 197
BioLineRx, Ltd., H2 2012 198
Amorfix Life Sciences Ltd., H2 2012 199
Piramal Healthcare Limited, H2 2012 200
Celltrion, Inc., H2 2012 201
Bio-Path Holdings, Inc., H2 2012 202
BioSante Pharmaceuticals, Inc., H2 2012 203
ZIOPHARM Oncology, Inc., H2 2012 204
Millennium Pharmaceuticals, Inc., H2 2012 205
Novartis AG, H2 2012 206
BioMarin Pharmaceutical Inc., H2 2012 207
Daewoong Pharmaceutical Co., Ltd., H2 2012 208
Eisai Co., Ltd., H2 2012 209
Gedeon Richter Plc., H2 2012 210
Glenmark Pharmaceuticals Ltd., H2 2012 211
ImmunoGen, Inc., H2 2012 212
Nippon Shinyaku Co., Ltd., H2 2012 213
Pfizer Inc., H2 2012 214

List of Figures
Number of Products under Development for Leukemias, H2 2012 38
Products under Development for Leukemias – Comparative Analysis, H2 2012 39
Products under Development by Companies, H2 2012 40
Products under Investigation by Universities/Institutes, H2 2012 56
Late Stage Products, H2 2012 74
Mid Clinical Stage Products, H2 2012 75
Early Clinical Stage Products, H2 2012 76
Discovery and Pre-Clinical Stage Products, H2 2012 77
Assessment by Monotherapy Products, H2 2012 356
Assessment by Combination Products, H2 2012 357
Assessment by Route of Administration, H2 2012 358
Assessment by Stage and Route of Administration, H2 2012 359
Assessment by Molecule Type, H2 2012 360
Assessment by Stage and Molecule Type, H2 2012 361

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos